The market competition of advanced pharmaceutical intermediate is relatively mild. Its relatively high added value is the main object of outsourcing and customized production for pharmaceutical enterprises. Also,the product differentiation is relatively big and customer loyalty relatively high, and the company has increased its bargaining power, so the competition is relatively mild now.
There are many kinds of pharmaceutical intermediates, and most of them are developed specifically for a certain kind of API or preparation. Limited by the specificality of the products used and the high investment in the early stage, there will not be too many manufacturers of certain pharmaceutical intermediate on the market, usually two or three. Product quality has a relative advantage. The company's existing products have obvious advantages over its competitors. For example, Aza-2'-deoxycytidine and FADCP, the intermediates of the main products for anti-AIDS drugs, have a market share of 55-60% in the domestic market. The products not only have fine colors, but also their purity is higher than that of other manufacturers' products, reducing the content of single impurity to the lowest level. Cooperative development of advanced intermediates. In recent years, the company has been vigorously developing quinolones intermediates and collaborating with universities to develop chiral drug intermediates. Collaborative projects currently under operation: Anti-AIDS drug abacavir intermediate (1R, 4S)-1-amino-4-hydroxymethyl-2-cyclopentenehydrochloride, in cooperation with Beijing University of Chemical Technology, and Des[3-Acetyl-5-(2-dimethylamino)ethyl] Diltiazem, in cooperation with East China University of Science and Technology.